Sacubitril/Valsartan for CKD5 Stage Dialysis Patients With Heart Failure

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Hemodialysis or peritoneal dialysis CKD5 patients with heart failure were randomly divided into Sacubitril/Valsartan and irbesartan treatment groups. Comparing the survival rates, the cardiac function, renal function, blood pressure success rate, and adverse reactions of two groups, to evaluate whether the efficacy and safety of Sacubitril/Valsartan in the treatment of patients with CKD dialysis combined with heart failure is superior to that of irbesartan.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ruijin Hospital
• Treatments: Irbesartan; Valsartan

Criteria

Inclusion Criteria:

• CKD stage 5, starting regular hemodialysis or peritoneal dialysis for more than 1 month.

• NT-proBNP ≥2000pg/ml.

• Voluntary informed consent.

Exclusion Criteria:

• Unable to tolerate ACEI/ARB class antihypertensive drugs;

• History of symptomatic hypotension/systolic blood pressure <100mmHg at screening;

• Potassium >6.0mmol/L;

• History of angioedema;

• Abnormal liver function such as ALT and/or AST >=3 times normal upper limit (ULN), total bilirubin >= 2 times ULN;

• Moderate to severe anemia (hemoglobin <80g/L);

• Cardiac surgery/intervention/cardiac resynchronization therapy has been performed in the past 3 months or is planned in the next 12 months;

• Newly found malignant tumor (within 3 years), or undergoing radiotherapy/chemotherapy;

• Pregnant and lactating women, or those of childbearing age who are unable to guarantee effective contraception;

• New and serious life-threatening infections;

• Active infectious diseases such as active tuberculosis, active viral hepatitis and HIV infection;

• Persons suffering from mental disorders and taking psychotropic drugs;

• Patients with life expectancy less than 12 months;

• The doctor assessed that the patient was not easy to follow up or had poor compliance and was not suitable for enrollment;

• Patients who do not want to sign informed consent.